Advanced Life Sciences Announces Upcoming Shareholder Meeting and Proxy Vote

CHICAGO, April 1 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) will conduct its annual shareholder meeting at 11:00 a.m. (central time) at the Company's offices located at 1440 Davey Road, Woodridge, IL 60517.  

(Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)

The Company issued a reminder to those shareholders that received proxy materials in connection with the annual meeting of shareholders and have not yet voted that their vote is important. Only shareholders who held the Company's stock as of the record date of February 8, 2010 are eligible to vote.  Those shareholders that have received proxy materials should utilize one of the options below to ensure that their vote is promptly recorded in time for the shareholders meeting:

• VOTE BY TOUCHTONE PHONE:  Votes may be cast by calling 1-866-540-5760. Shareholders will need to reference the control number that is found on the proxy card received by mail.
• VOTE THROUGH THE INTERNET: Votes may be cast by logging into: http://www.proxyvoting.com/adls.  Shareholders will need to reference the control number that is found on the proxy card received by mail.
• VOTE BY MAIL: Shareholders may cast their vote by mail by signing, dating and mailing the proxy card that was received by mail.

Those shareholders that have any questions relating to the shareholder meeting, voting methods, or need to request additional proxy materials should call the Company's proxy solicitation advisors The Altman Group toll-free at 1-800-217-0538 between the hours of 8:00 a.m. and 9:00 p.m. (central time), Monday through Friday.

Advanced Life Sciences plans to issue a press release detailing the results of the vote promptly following the meeting.  

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, Restanza, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CABP and biodefense pathogens including anthrax, plague and tularemia. For more information, please visit us on the web at www.advancedlifesciences.com or follow us on twitter at http://twitter.com/advancedlifesci.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.  These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission.  Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

SOURCE Advanced Life Sciences Holdings, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED